Singapore National Eye Centre will NEVER ask you to transfer money over a call. If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg.

Corneal & External Eye Disease

Synonym(s):

The Corneal & External Eye Disease Department is led by Professor Marcus Ang (Head and Senior Consultant) and comprises 8 ophthalmologists, providing medical and surgical care.


Our Care Services

The department provides a full range of corneal transplant services:

Transplant & Surgical Services:

  • Full-thickness and partial-thickness transplant
  • Stem cell reconstruction
  • Artificial cornea implants like the Boston keratoprosthesis for severe corneal disease

Other Conditions:

  • Corneal infections
  • Scars and dystrophies
  • Contact lens-related issues
  • Ocular surface disorders
  • Dry eyes

Medical Contact Lens Service:

We are one of the few medical contact lens services available in the region.

  • Specialty corneal gas permeable lenses to scleral lenses

Why Choose SNEC?

Quality Assurance

  • The first-year transplant survival rate is close to 95%, comparable to that of the top transplant centres in the world.
  • Started in 1991, the Corneal Transplant Registry now holds data from over 8,000 patients, making it one of Asia's largest*. It supports quality audits, research and evidence-based care by capturing data before, during, and after surgery.

Access to Advanced Lens Technology

  • Use femtosecond lasers for corneal transplant procedures, enabling clean and accurate cuts with minimal tissue damage which allows faster healing outcomes.
  • Among the first centres in the world to introduce Descemet Membrane Endothelial Keratoplasty (DMEK), a minimally invasive corneal transplant technique that offers a relatively safer and simpler procedure. With corneas supplied by the SEB, surgery takes about 30 minutes and restores vision within weeks.

Training the Experts

  • As SNEC is a WHO Collaborating Centre, it trains surgeons in the region and partners with the Singapore Eye Bank (SEB) to perform transplant surgeries using high-quality donor tissue.

8
ophthalmologists

 

> 22,900
outpatient visits a year

 

> 60%

of corneal transplants in Singapore are done at SNEC

 

“Our surgical techniques and advances in transplant technology have enabled our patients to regain clearer vision, faster and with less risk of post-operative complications.” 

Prof Marcus Ang

Head and Senior Consultant

Corneal and External Eye Disease Department

Our Care Team

News

Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."
30 Apr 2026 Read Story
Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.
05 Mar 2026 Read Story
Announcements Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally.
28 Jan 2026 Read Story